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Cancer of the pancreas accounts for some 3% of cancer in both
sexes combined, with about 6000 new cases a year (Cooper et al,
2005). The only established risk factor for pancreatic cancer is
tobacco smoking (Lowenfels, 1984). Incidence has fallen some
10–15% since the mid-1970s in men but has risen slightly in
women, and annual incidence in both sexes is now similar at about
10 per 100 000 (Quinn et al, 2001). Both incidence and mortality
rates may be biased, however, by under-registration of incident
cases and an over-certification of deaths (Remontet et al, 2003). In
this context, the survival of patients who were registered with a
diagnosis of pancreatic cancer in life assumes particular impor-
tance as a measure of outcome. Pancreatic cancer has one of the
worst prognoses: the European mean relative 5-year survival rate
for patients diagnosed during 1990–1994 was less than 4% (Sant
et al, 2003).
We analysed the data for 62 815 patients registered with
pancreatic cancer in England and Wales during the period
1986– 1999, only 74% of those were apparently eligible. More than
a fifth (22%) of all cases had to be excluded from survival analysis
because their recorded survival was zero (date of diagnosis same as
date of death): some will in fact have died on the day of diagnosis,
but most were registered from a death certificate only (DCO), and
their survival time was unknown. Some 3% of cases in the national
data were known to have been DCOs, but the proportion varied by
registry, and they could not be reliably distinguished from cases
with true zero survival in the national data. The proportion of
cases whose recorded survival was zero rose from 12 to 14% in the
1970s to 19–22% in the 1990s (Coleman et al, 1999). As they
represent such a large proportion of patients who were otherwise
eligible for survival analysis, and who may have shorter than
average survival (Berrino et al, 1995), the impact of their exclusion
on observed trends and inequalities in survival needs to be
considered. Nationally, the proportion of such cases fluctuated
slightly within the range 19–25%. Trends in the proportion of such
cases, however, varied very widely among regions: stable and
relatively low (6–11%) in Northern and Yorkshire, East Anglia and
Oxfordshire; initially high but falling rapidly (Thames, Wales); or
initially low but rising rapidly (South and West, West Midlands).
These patterns are hard to interpret, as the efficiency and
timeliness of registration have increased over this period, and
the proportion of other cancers registered solely from a death
certificate has generally declined. Overall estimates of survival may
thus be slightly high. In contrast, the impact of exclusions for zero
survival on trends in the deprivation gap in survival during the
1990s is likely to have been small or negligible, as there was no
systematic difference in the proportion of such cases among
socioeconomic groups (data not shown). The vital status of 1.4% of
patients was unknown at 5 November 2002, and a further 2.8%
were also excluded because pancreatic cancer was not their first
primary malignancy.
SURVIVAL TRENDS
Short-term survival has increased slightly in men, but there is no
evidence of improvement in longer-term survival in either sex
(Figure 1). One-year survival rose slightly from around 12% for
men diagnosed during the 10 years 1986– 1995 to 13.9% for
those diagnosed during 1996– 1999. The fitted, deprivation-
adjusted average increase of 1.6% every 5 years was statistically
significant (Table 1). For women, 1-year survival rose very slowly,
from 10.9 to 12.1%, with an average increase of just 0.3% every 5
years. There was, however, no improvement at all in 5-year
survival, which was actually slightly lower for those diagnosed
during 1996–1999 (2.7% in men, 2.3% in women) than for those
diagnosed during 1986–1990 (3.1 and 2.5%, respectively). Median
survival is less than 6 months in both sexes, and it did not
improve.
Short-term predictions of survival for patients diagnosed during
2000– 2001, using hybrid analysis (Brenner and Rachet, 2004),
show no evidence of any pending improvement in survival up to 10
years after diagnosis (Table 1).
DEPRIVATION
Differences in survival between deprivation categories were
small. For those diagnosed during the late 1990s, the depriva-
tion gap in 1- and 5-year survival was slightly more marked
in men (Table 2, Figure 2). For women diagnosed in 1996–1999,
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5-year survival was slightly better in the deprived than the
affluent (deprivation gap positive, þ 1.1%) and this difference
was of borderline statistical significance. The deprivation
gap in survival for women diagnosed during the 14 years
1986– 1999 appears to have fallen for 1-year survival or even
reversed for 5-year survival, but the fitted average improvement
every 5 years was less than 1%, and this trend was not statistically
significant. There was no systematic trend towards better survival
in the deprived than the affluent, and short-term predictions of
survival for patients diagnosed during 2000–2001, using
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated
with cohort or complete approach (1986–1990, 1991–1995,
1996–1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%)
by sex and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001.
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 12.4 (11.8, 13.0) 12.2 (11.6, 12.8) 13.9 (13.2, 14.6) 1.6* (0.2, 3.0) 13.6 (12.6, 14.6)
Women 10.9 (10.3, 11.5) 11.6 (11.0, 12.2) 12.1 (11.5, 12.8) 0.3 (0.9, 1.6) 11.5 (10.6, 12.5)
5 years Men 3.1 (2.8, 3.5) 2.5 (2.2, 2.8) 2.7 (2.3, 3.1) 0.1 (0.6, 0.9) 2.6 (2.2, 3.2)
Women 2.5 (2.2, 2.8) 2.2 (1.9, 2.5) 2.3 (1.9, 2.7) 0.8* (1.4, 0.1) 2.0 (1.6, 2.5)
10 years Men 2.6 (2.3, 3.0) 2.0 (1.7, 2.3) 0.6 (0.7, 1.9) 2.1 (1.7, 2.7)
Women 2.1 (1.8, 2.4) 1.8 (1.5, 2.1) 0.5 (0.7, 1.7) 1.8 (1.4, 2.2)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05.
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hybrid analysis, do not suggest any imminent change in the
deprivation gap.
COMMENT
Relative survival at 5 years, less than 3% in both sexes, is lower
than for any other of the 20 most common adult cancers in England
and Wales. No improvement has occurred since the 1970s (Coleman
et al, 1999). Despite progress in diagnostic procedures, most cases are
still metastatic at diagnosis, and are not amenable to surgical
resection of curative intent. Even when curative surgery can be
attempted, most patients will relapse. A small trial has shown
that palliative chemotherapy may extend median survival from
2.5 to 6 months (Glimelius et al, 1996), but efficacy remains
disappointing, and any therapeutic progress over the last 30 years has
not been reflected in higher survival for all patients with pancreatic
cancer.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men 0.9 (2.7, 1.0) 3.2** (5.0, 1.4) 2.8* (4.9, 0.6) 1.1 (2.6, 0.4) 3.4* (6.4, 0.5)
Women 1.5 (3.3, 0.2) 3.5** (5.3, 1.8) 0.5 (2.5, 1.4) 0.4 (1.0, 1.7) 1.0 (3.7, 1.7)
5 years Men 0.0 (1.0, 1.1) 1.2** (2.1, 0.3) 0.9 (2.2, 0.4) 0.6 (1.5, 0.3) 0.6 (2.0, 0.8)
Women 0.4 (1.3, 0.6) 0.9* (1.8, 0.1) 1.1* (0.1, 2.1) 0.7 (0.0, 1.4) 0.5 (0.5, 1.5)
10 years Men 0.7 (0.3, 1.7) 0.8 (1.8, 0.1) 1.5* (2.9, 0.1) 0.5 (2.0, 0.9)
Women 0.2 (0.8, 1.1) 0.9* (1.8, 0.0) 1.1 (2.3, 0.2) 0.5 (0.4, 1.5)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). * Po0.05; **Po0.01.
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